ArticleAbdominal radiology (New York)2026
Transperineal 3D vector magnetic resonance elastography of the prostate is feasible in men with benign prostatic hyperplasia and lower urinary tract symptoms.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo establish feasibility of 3D vector magnetic resonance elastography of the prostate (pMRE) with a novel transperineal passive driver in men with benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
methodsFollowing informed consent, 21 men (median age: 41 years, IQR: 35-61) without (n = 6) or with mild (n = 9) and moderate/severe (n = 6) LUTS underwent multiparametric prostate MRI including pMRE, on a 3.0T MRI using a commercially available active driver and prototype transperineal passive driver. Prostate volume (PV), prostatic urethra length (PUL), postvoid residual (PVR) and bladder wall thickness (BWT) were measured. Regions-of-interest were drawn on the prostate TZ shear stiffness maps at the base and midgland. Mean TZ shear stiffness was calculated. The product of mean TZ shear stiffness and PUL [kPa x U length] were calculated. LUTS severity and uroflowmetry parameters, including peak (Qmax) and average (Qave) urine flow were measured with the International Prostate Symptom Score (IPSS) and a uroflowmeter, respectively. The Kruskal-Wallis rank sum test and Spearman correlation coefficients were used to assess relationships between imaging and clinical data. A p-value of < 0.05 was considered statistically significant.
resultsMen with moderate/severe LUTS (median IPSS: 20, IQR: 13.25-23.25) were older (p = 0.008), had a higher BMI (p = 0.044), and a lower Qmax (p = 0.005) and Qave (p = 0.017) compared to men without and with mild LUTS. PV and PVR were similar across groups. Stiffness analysis included 19 men. Higher midgland TZ shear stiffness correlated with lower Qmax (ρ = -0.57; p = 0.017). Increase in [kPa x U length] correlated with a lower Qmax (ρ = -0.59; p = 0.015) and Qave (ρ = -0.51; p = 0.04). The correlation between Qmax, Qave and voided volume was higher with [kPa x U length] compared to mean TZ shear stiffness alone.
conclusionspMRE with a novel transperineal passive driver is feasible and can be used to measure TZ shear stiffness. Higher TZ shear stiffness and longer PUL are associated with voiding dysfunction in men with moderate/severe LUTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.